Defitelio
Total Payments
$29.6M
Transactions
2,724
Doctors
554
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $19.0M | 1,188 | 263 |
| 2017 | $10.6M | 1,536 | 376 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28.6M | 709 | 96.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $534,910 | 175 | 1.8% |
| Consulting Fee | $257,827 | 92 | 0.9% |
| Travel and Lodging | $176,970 | 558 | 0.6% |
| Food and Beverage | $69,358 | 1,182 | 0.2% |
| Grant | $2,000 | 1 | 0.0% |
| Education | $306.52 | 7 | 0.0% |
Payments by Type
Research
$28.6M
709 transactions
General
$1.0M
2,015 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Adaptive Study Comparing the Efficacy andSafety of Defibrotide vs Best Supportive Care in the Prevention ofHepatic Veno-Occlusive Disease in Adult and Pediatric PatientsUndergoing Hematopoietic Stem Cell Transplant | Jazz Pharmaceuticals Inc. | $8.3M | 2 |
| A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients | Jazz Pharmaceuticals Inc. | $6.6M | 0 |
| A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant | Jazz Pharmaceuticals Inc. | $5.4M | 0 |
| A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant | Jazz Pharmaceuticals Inc. | $4.1M | 1 |
| The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloablative Conditioning MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell CD3 Addback | Jazz Pharmaceuticals Inc. | $1.5M | 0 |
| Defibrotide TMA Prophylaxis Pilot Trial | Jazz Pharmaceuticals Inc. | $714,196 | 0 |
| Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome | Jazz Pharmaceuticals Inc. | $356,895 | 0 |
| Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients | Jazz Pharmaceuticals Inc. | $313,510 | 0 |
| Safety and Efficacy of ProphylacticDefibrotidein Children, Adolescents, and Young Adults With Sickle Cell Disease Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell CD3 Addback | Jazz Pharmaceuticals Inc. | $243,750 | 0 |
| An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease AGvHD | Jazz Pharmaceuticals Inc. | $140,298 | 0 |
| Defibrotide for the prevention of GVHD | Jazz Pharmaceuticals Inc. | $127,463 | 0 |
| A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome | Jazz Pharmaceuticals Inc. | $116,217 | 0 |
| DEFIBROTIDE AS A RENAL THERAPEUTIC AGENT | Jazz Pharmaceuticals Inc. | $112,500 | 0 |
| Role of Defibrotide in the prevention of graft versus host disease after allogeneic hematopoietic cell transplantation | Jazz Pharmaceuticals Inc. | $106,219 | 0 |
| A Pilot Trial of Using Pre-Transplant Risk Stratification and Prophylactic Defibrotide to Prevent Serious Thrombotic Microangiopathy in High-Risk Hematopoietic Stem Cell Transplant Patients | Jazz Pharmaceuticals Inc. | $104,402 | 0 |
| Defibrotide as a Renal Therapeutic Agent | Jazz Pharmaceuticals Inc. | $99,997 | 0 |
| Role of Defibrotide in modulating microvascular endothelial cell pathology induced by plasmas from patients with primary and secondary thrombotic microangiopathies | Jazz Pharmaceuticals Inc. | $68,448 | 0 |
| Role of Defibrotibe in the Prevention of Graft Versus Host Disease After Allogen | Jazz Pharmaceuticals Inc. | $63,956 | 0 |
| Role of Defibrotide in the Prevention of Graft Versus Host Disease After Allogen | Jazz Pharmaceuticals Inc. | $63,956 | 0 |
| Defending theendothelium the contribution ofendothelial activation and injury tocomplications following allogenichematopoietic cell transplantation | Jazz Pharmaceuticals Inc. | $28,360 | 0 |
Top Doctors Receiving Payments for Defitelio — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology | Stanford, CA | $9,973 | 11 |
| , M.D | Hematology & Oncology | Boston, MA | $9,874 | 18 |
| , MD | Hematology & Oncology | Altamonte Springs, FL | $9,342 | 17 |
| , MD | Urology | Hudson, OH | $9,000 | 1 |
| , MD | Pediatric Hematology-Oncology | San Francisco, CA | $8,796 | 14 |
| , MD | Medical Oncology | Durham, NC | $7,799 | 9 |
| , MD | Pediatrics | Duarte, CA | $7,678 | 3 |
| , M.D | Pediatrics | Palo Alto, CA | $7,507 | 7 |
| , MD | Pediatric Hematology-Oncology | Tacoma, WA | $7,500 | 2 |
| , M.D | Pediatrics | Omaha, NE | $6,932 | 14 |
| , MD | Hematology & Oncology | Charlotte, NC | $6,725 | 8 |
| , M.D | Pediatric Hematology-Oncology | Jackson, MS | $6,110 | 8 |
| , M.D | Hematology & Oncology | Houston, TX | $5,560 | 10 |
| , M.D | Pediatric Radiology | Leawood, KS | $5,453 | 9 |
| Bart Scott | Medical Oncology | Seattle, WA | $5,249 | 9 |
| , MD | Gastroenterology | Seattle, WA | $5,178 | 7 |
| , MD | Medical Oncology | Saint Louis, MO | $5,007 | 10 |
| , MD | Nephrology | Boston, MA | $5,000 | 1 |
| , MD | Pediatric Hematology-Oncology | Pittsburgh, PA | $4,988 | 9 |
| , MD | Internal Medicine | Orlando, FL | $4,978 | 30 |
| , M.D | Pediatric Hematology-Oncology | Cleveland, OH | $4,843 | 22 |
| , MD | Pediatric Hematology-Oncology | Wilmington, DE | $4,499 | 16 |
| , MD | Medical Oncology | Saint Louis, MO | $4,426 | 8 |
| , M.D | Internal Medicine | Houston, TX | $4,418 | 6 |
| John Galvin | — | Chicago, IL | $4,353 | 6 |
Ad
Manufacturing Companies
- Jazz Pharmaceuticals Inc. $29.6M
Product Information
- Type Drug
- Total Payments $29.6M
- Total Doctors 554
- Transactions 2,724
About Defitelio
Defitelio is a drug associated with $29.6M in payments to 554 healthcare providers, recorded across 2,724 transactions in the CMS Open Payments database. The primary manufacturer is Jazz Pharmaceuticals Inc..
Payment data is available from 2017 to 2018. In 2018, $19.0M was paid across 1,188 transactions to 263 doctors.
The most common payment nature for Defitelio is "Unspecified" ($28.6M, 96.5% of total).
Defitelio is associated with 20 research studies, including "A Phase 3, Randomized, Adaptive Study Comparing the Efficacy andSafety of Defibrotide vs Best Supportive Care in the Prevention ofHepatic Veno-Occlusive Disease in Adult and Pediatric PatientsUndergoing Hematopoietic Stem Cell Transplant" ($8.3M).